| Identification | Back Directory | [Name]
L-Serinamide, N2-acetyl-L-lysyl-L-tryptophyl-L-lysyl-L-seryl-L-phenylalanyl-L-leucyl-L-lysyl-L-threonyl-L-phenylalanyl-L-lysyl-L-seryl-L-alanyl-L-alanyl-L-lysyl-L-threonyl-L-valyl-L-leucyl-L-histidyl-L-threonyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-isoleucyl-L-seryl- (9CI) | [CAS]
850761-47-6 | [Synonyms]
L-Serinamide, N2-acetyl-L-lysyl-L-tryptophyl-L-lysyl-L-seryl-L-phenylalanyl-L-leucyl-L-lysyl-L-threonyl-L-phenylalanyl-L-lysyl-L-seryl-L-alanyl-L-alanyl-L-lysyl-L-threonyl-L-valyl-L-leucyl-L-histidyl-L-threonyl-L-alanyl-L-leucyl-L-lysyl-L-alanyl-L-isoleucyl-L-seryl- (9CI) | [Molecular Formula]
C138H226N36O34 | [MOL File]
850761-47-6.mol | [Molecular Weight]
2933.49 |
| Hazard Information | Back Directory | [Uses]
Peceleganan (PL-5) is an artificial antimicrobial cecropin A (1-10) × melittin B (3-18) hybrid (10+16)-peptide analogue. Peceleganan inhibits wound infection[1]. | [in vivo]
Peceleganan (0.4 and 0.75 mg/mL for 100 μL; transdermal; twice daily for 3 days) inhibits Staphylococcus aureus in the mouse infection model[2]. | Animal Model: | ICR male mice (20-25 g), S. aureus ATCC 25923 wound infection model[2] | | Dosage: | 0.4 and 0.75 mg/mL for 100 μL | | Administration: | Transdermal administration, twice daily for 3 days | | Result: | Significantly reduced the amount of bacteria. |
| [References]
[1] WHO Drug Information. International Nonproprietary Names for Pharmaceutical.
[2] Feng Q, et al. Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo. Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):197-204. DOI:10.1007/s10096-014-2219-3 |
|
|